Back to search results

Contingency Management Plus Deep Transcranial Magnetic Stimulation for Cocaine Use Disorder

This study is looking at how well a combination of two treatments works for people with Cocaine Use Disorder (CUD). The treatments are Contingency Management (CM), which offers rewards for staying off cocaine, and Deep Transcranial Magnetic Stimulation (TMS), a device that uses magnetic fields to stimulate the brain. Researchers want to see if this combination helps people who haven't responded to other treatments. You might be able to join if you are between 18 and 65 years old, have moderate-to-severe CUD, and have recently used cocaine. The study will measure success by how many participants test negative for cocaine in urine tests and how much their cocaine cravings decrease over 11 weeks. The current status of this study is unclear.

Study design
This interventional study plans to enroll 100 participants. It will compare active Transcranial Magnetic Stimulation (TMS) with a sham (inactive) TMS, both combined with Contingency Management (CM).
What's involved
You would have clinic visits three times a week (Monday, Wednesday, and Friday) to provide urine samples and discuss substance use. You would also receive either active or sham TMS treatments.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes, like cocaine use and craving, will be measured from the start of the study up to Week 11.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07490600

Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment of Cocaine Use Disorder

Recruiting
NAAges 18–65InterventionalTreatment
The University of Texas Health Science Center, Houston
~100 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Contingency Management (CM)Transcranial Magnetic Stimulation (TMS) ShamTranscranial Magnetic Stimulation (TMS) experimental

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants who test negative for cocaine use as assessed by urine drug screen
Measured over from Baseline to Week 11
+1 more outcome measured

Conditions

Cocaine Use Disorder (CUD)

Explore related trials

Cocaine Use Disorder

NCT07490600

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas Health Science Center at Houston

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joy M Schmitz, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

Joy M Schmitz, PhD
[email protected]
(713) 486-2867
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study.
Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for moderate-to-severe CUD and report recent cocaine use (verified by at least one positive urine drug screen (UDS) for the cocaine metabolite benzoylecgonine (BE), during intake).
Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).
Women of child-bearing potential must provide negative urine pregnancy test prior to randomization.
Be able to provide the names and contact information of at least 2 persons who can consistently locate their whereabouts

Exclusion

Current DSM-5 diagnosis for substance use disorder (of at least moderate severity) other than cocaine, cannabis, or nicotine or a substance Use Disorder (SUD) requiring medical detoxification (e.g., alcohol, opioid, benzodiazepine)
Presence of any medical, neurological, psychiatric, or physical condition, disease, or illness (including psychosis and bipolar disorder) that, in the opinion of the PIs and the Certified Registered Nurse Anesthetist (CNRA)Medical Director could: (a) compromise interfere, limit, or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data.
Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments:
Any contraindications to MRI scans (metal in the body; claustrophobia). -Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil).
History of brain surgery.
History of an intracranial lesion or any medical or neurological diagnosis/condition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension/Pseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches \> 15 days/month, loss of vision or decreased vision
Moderate-to-severe heart disease.
History of stroke.
Taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the study physician; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:
Personal history of epilepsy or seizure disorder and/or family history including a first degree relative
Serious head injury with loss of consciousness
Having conditions of probation or parole requiring reports of drug use to officers of the court or impending incarceration
For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope/ presyncope related to noxious stimuli, anxiety, micturition, or posture).
Pregnant or nursing for female participants
Inability to read, write, or speak English.

What this trial measures

  • Number of participants who test negative for cocaine use as assessed by urine drug screenfrom Baseline to Week 11

    this will be measured measured 3 times per week throughout the study

  • Cocaine craving as assessed by cocaine craving questionnaire (CCQ)from Baseline to Week 11

    this will be administered weekly. This is a 45 item questionnaire and each is scored on a Likert scale from 1( strongly disagree), to 7(strongly agree). Score range is 45 (minimum) - 315 (maximum).Higher scores indicate greater cocaine craving.